Swiss major Novartis sought regulatory approval in India to initiate Phase III clinical trials for its drug, Ruxolitinib used in the treatment of Covid 19. These trials were part of a global study that the company started in May to evaluate the use of Ruxolitinib (sold as Jakavi) for treatment...